Thursday November 26 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

GENFIT

Genfit is a biopharmaceutical company, listed on Alternext by Euronext™ Paris (ALGFT - FR0004163111) with headquarters in Lille, France and a US subsidiary in Cambridge, Massachusetts.

Through its world-renowned scientific expertise, particularly in the field of nuclear receptors, Genfit’s research efforts are focused on the discovery and development of new treatments mainly in the growing therapeutic areas of Cardiometabolic and Neurodegenerative disorders, such as prediabetes/diabetes, atherosclerosis, dyslipidemia, obesity, and Alzheimer’s. Genfit uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments to address these major public health problems and their unmet medical needs.

Genfit has an original business model built on both proprietary internal programs and a strong track record of partner-supported programs and collaborations. This strategy allows the company to efficiently manage the risks associated with the internal programs, and at the same time build value for its shareholders. Genfit, on its own or in collaboration with its major pharmaceutical partners, has thus created a rich and diversified pipeline of drug candidates in pre-clinical and clinical development, as well as a broad intellectual property portfolio.

Genfit’s strong portfolio of therapeutic products, tools, and clinical biomarkers, together with its scientific expertise, have made the Company into a European biotechnology leader.


Contact Details:
Parc Eurasanté – Lille Métropole 885, avenue Eugène Avinée
LOOS
59120
France
Tel:+33 (0)3 20 16 40 00
Fax:+33 (0)3 20 16 40 01
Email:contact@genfit.com
WWW:

www.GENFIT.com




Recent Publications by GENFIT:

On the central mechanism underlying ghrelin's chronic pro-obesity effects in rats: new insights from studies exploiting a potent ghrelin receptor antagonist.
In the present study, we explore the central nervous system mechanism...
26th August, 2009
Department of Physiology/Endocrinology, Institute of Neuroscience and J Neuroendocrinol. 2009 Sep;21(9):777-85.
DOI Direct Link
Phosphorylation of farnesoid X receptor by protein kinase C promotes its transcriptional activity.
The farnesoid X receptor (FXR, NR1H4) belongs to the nuclear receptor...
12th June, 2009
GENFIT, Loos-Lez-Lille, France. Mol Endocrinol. 2008 Nov;22(11):2433-47. Epub 2008 Aug 28.
DOI Direct Link
Safety issues and prospects for future generations of PPAR modulators.
Because of their wide range of actions on glucose homeostasis, lipid...
5th October, 2007
Genfit, F-59006 Loos, France. Biochim Biophys Acta. 2007 Aug;1771(8):1065-81. Epub 2007 Feb 24.
DOI Direct Link
Farnesoid X receptor represses hepatic lipase gene expression.
The farnesoid X receptor (FXR) is a nuclear receptor that regulates gene...
22nd April, 2005
GENFIT, Parc Eurasante, Loos, France. J Lipid Res. 2004 Nov;45(11):2110-5. Epub 2004 Sep 1.
DOI Direct Link
The liver X receptor ligand T0901317 down-regulates APOA5 gene expression through activation of SREBP-1c.
Alterations in the expression of the recently discovered apolipoprotein A5...
16th December, 2004
Departement d'Atherosclerose, UR545 INSERM, Institut Pasteur de Lille and J Biol Chem. 2004 Oct 29;279(44):45462-9. Epub 2004 Aug 17.
DOI Direct Link

View more GENFIT research publications.

BioNews Results for GENFIT:

Genfit Pursues Research In The Therapeutic Application Of Nuclear Receptor Modulators To Stem Cell Biology
Quote.com France:  Nov 12 2009 9:43AM Matching: genfit
GENFIT PURSUES RESEARCH IN THE THERAPEUTIC APPLICATION OF NUCLEAR RECEPTOR MODULATORS TO STEM CELL BIOLOGY
Individual.com:  Nov 12 2009 7:10AM Matching: genfit
PR: genOwayEURs expertise selected as part of the AD-Inov consortium
Pharma Live:  Sep 10 2009 2:07PM Matching: genfit

GENFIT Patents:

US Patent No.Title
7566737 Combinations of substituted 1,3-diphenylprop-2-en-1-one derivatives with other therapeutically active ingredients
7547729 1,3-diphenylprop-2-en-1-one derivative compounds, preparation method thereof and uses of same
7547543 Method for identifying substances useful for treating inflammation using the response element to the ikbalpha ROR receptor
7385082 Preparation of 1,3-diphenylprop-2-en-1-one derivatives
7375135 Fatty acid derivatives; preparation and uses thereof

View more GENFIT patents.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 768 times since April 2007, the link to the organisation's website has been followed 76 times

Recent Search Terms used to find this page: genfit | Genfit Lille | genfit patent | GENFIT | GENFIT | Genfit | .

Search for more companies in LOOS

Search for more companies in



This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for GENFIT

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.